Overview

Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to continue to assess the safety of certolizumab pegol in combination with methotrexate (MTX).
Phase:
Phase 3
Details
Lead Sponsor:
UCB Pharma
Treatments:
Certolizumab Pegol